DS7300-203 (IDeate-Pantumor02)
A phase 1b/2 pan-tumor, open-label study to evaluate the efficacy and safety of ifinatamab deruxtecan (i-dxd) in subjects with recurrent or metastatic solid tumors
Detalhes
Destaques